Balancing “make, buy and ally” in life sciences

Download the article to read all the content on which this summary is based.

Balancing make, buy and ally is one of the key drivers of corporate value for life sciences companies. In many cases, business alliances prevail as a way to boost innovation and growth in addition to in-house innovation efforts (make) and active merger and acquisitions efforts (buy).

The biggest fear when entering an alliance is giving away too much information and receiving too little in return.

Despite significant value add, many business alliances fail to deliver the expected value.

Read the full article to find out how companies could manage their business alliance portfolios to help them reach their full potential.

The article was written by:

  • Dr. Renata Jovanovic
    Senior Manager, Advisory Services, Performance Improvement, Ernst & Young GmbH, Germany
  • Juan Sebastian Etchart
    Senior Manager, Advisory Services, Performance Improvement, Ernst & Young GmbH, Germany
  • Frank Broetzmann Partner
    Advisory Services - Performance Improvement, Ernst & Young GmbH, Germany

Read the full article pdf602.28 kB

EY refers to one or more of the member firms of Ernst & Young Global Limited (EYG), a UK private company limited by guarantee. EYG is the principal governance entity of the global EY organization and does not provide any service to clients. Services are provided by EYG member firms. Each of EYG and its member firms is a separate legal entity and has no liability for another such entity's acts or omissions. Certain content on this site may have been prepared by one or more EYG member firms